title: [The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
abstract: A 18-year old female with acute myelogenous leukemia (AML), M2 had translocation: t(6;9) (p23; q34). The patient entered into hematological complete remission after two courses of BHAC-DMP chemotherapy with disappearance of cytogenetic abnormality. However, minimal residual disease (MRD) detected with DEK/CAN chimeric m-RNA by reverse transcription polymerase chain reaction (RT-PCR) was continuously observed, although decreased quantitatively, following several courses of consolidation and intensification chemotherapies. MRD was detected also in the harvested peripheral blood stem cells (PBSC). Leukemia relapsed with the reappearance of t(6;9) 2 months after the subsequent peripheral blood stem cell transplantation (PBSCT). Leukemia became refractory to chemotherapy, and the patient died 5 months thereafter.
authors.affiliation: Division of Hematology, Yamaguchi Prefecture Central Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Toyosawa
authors.forename: K
authors.initials: K
authors.lastname: Shinohara
authors.forename: K
authors.initials: K
authors.lastname: Ariyoshi
authors.forename: T
authors.initials: T
authors.lastname: Ando
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Hikiji
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002896:Chromosomes, Human, Pair 6; D002899:Chromosomes, Human, Pair 9; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000628:therapy*; D015122:Mercaptopurine / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D018365:Neoplasm, Residual; D015513:Oncogene Proteins / Q000235:genetics*; D015514:Oncogene Proteins, Fusion; D016133:Polymerase Chain Reaction; D011239:Prednisolone / Q000008:administration & dosage; D012333:RNA, Messenger / Q000032:analysis*; D011993:Recombinant Fusion Proteins / Q000235:genetics; D014178:Translocation, Genetic
chemical_list: C104001:DEK-CAN fusion protein, recombinant; D015513:Oncogene Proteins; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; D003561:Cytarabine; D005047:Etoposide; D011239:Prednisolone; D008942:Mitoxantrone; D015122:Mercaptopurine; D003630:Daunorubicin